To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

NCT06352008 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Anlotinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital